|
Colorectal Carcinoma
|
0.510 |
AlteredExpression
|
disease |
BEFREE |
Suppression of PKD using the small molecule inhibitors CRT0066101 and kb-NB142-70 resulted in low micromolar in vitro antiproliferative activity against multiple human colorectal cancer cell lines.
|
24634417 |
2014 |
|
Adenocarcinoma
|
0.350 |
GeneticVariation
|
group |
BEFREE |
The PRKD1 E710D hotspot mutation is highly specific in separating polymorphous adenocarcinoma of the palate from adenoid cystic carcinoma and pleomorphic adenoma on FNA.
|
29266837 |
2018 |
|
Adenocarcinoma
|
0.350 |
GeneticVariation
|
group |
BEFREE |
Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands.
|
25240283 |
2014 |
|
Adenocarcinoma
|
0.350 |
GeneticVariation
|
group |
BEFREE |
Polymorphous (low-grade) adenocarcinomas are characterized by hot spot point E710D mutations in the PRKD1 gene, whereas cribriform adenocarcinoma of (minor) salivary glands origin are characterized by translocations involving the PRKD1-3 genes.
|
29076877 |
2018 |
|
Adenocarcinoma
|
0.350 |
GeneticVariation
|
group |
BEFREE |
Salivary gland polymorphous low-grade adenocarcinomas commonly harbor activating PRKD1 mutations.
|
25367945 |
2014 |
|
Adenocarcinoma
|
0.350 |
GeneticVariation
|
group |
BEFREE |
Lack of PRKD2 and PRKD3 kinase domain somatic mutations in PRKD1 wild-type classic polymorphous low-grade adenocarcinomas of the salivary gland.
|
26426580 |
2016 |
|
Metastatic melanoma
|
0.310 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study suggests, for the first time, that while cPKCs don't embody a pertinent therapeutic target, inhibition of PKD1 represents a novel attractive approach for the treatment of metastatic melanoma.
|
28056869 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite these advances, the mechanisms through which PKD contributes to the pathogenesis of cancer remain unknown.
|
22532599 |
2012 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we have discussed the structural-functional properties, activation mechanisms, signaling pathways and physiological functions of PKD in the context of human cancer.
|
28577984 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These newly retrieved hits were docked against our PKD1 protein model, and those displaying essential interactions are reported herein as new hits, which could serve as new leads for cancer research, especially pancreatic cancer.
|
29058231 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The protein kinase D (PKD) family is an emerging therapeutic target of cancer.
|
30018032 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although protein kinase D (PKD) has been shown to contribute to invasion and metastasis in several types of cancer, the role of PKD in the epithelial mesenchymal transition (EMT) of hepatocellular carcinoma (HCC) has remained unclear.
|
26683365 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, this study explained the molecular basis of PKD1 specific inhibition, which may help to design new selective inhibitors for better therapies to overcome cancer and PKD1 dysregulated disorders.
|
31131745 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We showed that PKD1 was downregulated in 26 of 34 cancer tissues in comparison with matched normal epitheliums.
|
25578563 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Protein kinase D1 (PKD1) plays a vital role in signal transduction, cell proliferation, membrane trafficking, and cancer; however, the majority of the studies up to date had centered primarily on PKD1 functions in interphase, very little is known about its role during cell division.
|
30997696 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we summarize the structural and functional aspects of PKD1 and highlight the pathobiological roles of this kinase in cancer.
|
21680539 |
2011 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The protein kinase D (PKD) family has emerged as a promising target for cancer therapy with PKD1 being most intensively studied; however, its role in HNSCC has not been investigated.
|
30419840 |
2018 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Protein kinase D1 (PKD1) protects cells from oxidative stress, and its abnormal activity serves an important role in multiple malignancies.
|
30896865 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PKD activity is also increasingly linked to cancer, immune regulation, pain modulation, memory, angiogenesis, and cardiovascular disease.
|
28174535 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent work from our and other laboratories has identified a profound metabolic reprogramming in PKD, similar to the one reported in cancer and consistent with the reported increased proliferation.
|
31816397 |
2019 |
|
Polycystic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
NPH and associated disorders are considered as ciliopathies, as all NPHP gene products are expressed in the primary cilia, similarly to the polycystic kidney disease (PKD) proteins.
|
18607645 |
2009 |
|
Polycystic Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Microarray expression analysis of kidneys from 30-day-old PCK rats revealed increased expression of genes previously identified in PKD renal expression profiles, such as inflammatory response, extracellular matrix synthesis, and cell proliferation genes among others, whereas the FHH.Pkhd1 did not show activation of these common markers of disease.
|
22669842 |
2012 |
|
Polycystic Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Oriented cell division (OCD) and convergent extension (CE) shape developing renal tubules, and their disruption has been associated with polycystic kidney disease (PKD) genes, the majority of which encode proteins that localize to primary cilia.
|
29033332 |
2017 |
|
Polycystic Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
ADPKD is caused by mutations in the polycystic kidney disease (PKD)1 or PKD2 gene, encoding polycystin (PC)-1 or PC-2, respectively.
|
15563610 |
2005 |
|
Polycystic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Discoidin Domain Receptor 1 (DDR1) tyrosine kinase is upregulated in PKD kidneys but does not play a role in the pathogenesis of polycystic kidney disease.
|
31260458 |
2019 |